nivolumab (Opdivo) + ipilimumab (Yervoy)

nivolumab (Opdivo) + ipilimumab (Yervoy)

Cancer cells may exploit “regulatory” pathways, such as checkpoint pathways, to hide from the immune system and shield the tumor from immune attack. Nivolumab (Opdivo) + ipilimumab (Yervoy) are immune checkpoint inhibitors that target separate, distinct and complementary checkpoint pathways (PD-1 and CTLA-4).1 which increases your body’s immune response.  The drugs activate immune cells—unleashing them, in effect—so that they can invade tumors and attack melanoma cells.

Ipilimumab blocks a checkpoint molecule called CTLA-4. CTLA-4 regulates the growth and activity of T cells, a type of white blood cell that attacks other cells in the body that look foreign, including some cancer cells. By blocking CTLA-4, ipilimumab activates your immune system against melanoma by allowing T cells to multiply and increase your body’s immune response.

Nivolumab blocks a different checkpoint molecule called PD-1, which helps protect tumor cells from being attacked by your immune system. Nivolumab removes the PD-1 “shield” to allow your immune system to find and attack melanoma cells.

Side Effects

It’s very important to report any new side effects during or after treatment to your health care team promptly.

Watch Now – Video on the side effects of Immunotherapies

Provincial Funding Summary

View Summary PDF

for Advanced Melanoma
This information is current as of August 1, 2019

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

Click Here to visit CADTH pan-Canadian Oncology Drug Review

Melanoma Newsletter

Get the latest melanoma news straight to your inbox. Sign up for the Melanoma Patient Exchange Newsletter.

Melanoma Support

The Melanoma Network of Canada has a number of free services for patients, caregivers and healthcare professionals.

Dr. Marcus Butler
Expanding Horizons in Melanoma Treatment

Menu